<DOC>
	<DOCNO>NCT00448279</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety continuation discontinuation Herceptin treatment combination 2nd line chemotherapy , patient HER2 positive metastatic breast cancer whose condition progress 1st line chemotherapy plus Herceptin . Patients randomize either continue discontinue Herceptin treatment ( 2mg/kg iv infusion weekly , 6mg/kg iv infusion every 3 week ) receive 2nd line chemotherapy investigator 's choice . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>THOR Study : A Study Continued Herceptin ( Trastuzumab ) Combination With Second Line Chemotherapy Patients With HER2 Positive Metastatic Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>female patient , &gt; =18 year age ; metastatic breast cancer ; HER2 overexpression ( IHC 3+ and/or FISH positive ) ; disease progression previous 1st line chemotherapy plus Herceptin ; schedule receive 2nd line chemotherapy . incompatibility previous Herceptin therapy ; pregnancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>